Brukinsa (Zanubrutinib) for Lymphoma

Overview
Brukinsa is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with various types of lymphoma, including mantle cell lymphoma (MCL) for those who have received at least one prior therapy; Waldenström’s macroglobulinemia; relapsed or refractory marginal zone lymphoma following at least one anti–CD20-based regimen; chronic lymphocytic leukemia or small lymphocytic lymphoma; and relapsed or refractory follicular lymphoma in combination with obinutuzumab after two or more lines of systemic therapy. Brukinsa is also known by its drug name, zanubrutinib.

Zanubrutinib belongs to the drug category of kinase inhibitors. It works by blocking the action of an enzyme involved in the growth of cancer cells, thereby slowing or stopping the progression of the disease.

How do I take it?
Prescribing information states that Brukinsa should be taken orally as a capsule, either one or twice daily, depending on the dosage. The medication should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Brukinsa include decreased neutrophil (white cell) count, decreased platelet count, upper respiratory tract infection, hemorrhaging (bleeding), and musculoskeletal pain.

Rare but serious side effects listed for Brukinsa include low blood cell counts, bleeding problems, other cancers, heart rhythm problems, and fetal harm in people who are pregnant.

For more information about this treatment, visit:

Label: Brukinsa — Zanubrutinib Capsule — DailyMed

Zanubrutinib — MedlinePlus